Original Publication Date: 4 March, 2014
Publication / Source: Lung Cancer Management
Authors: Timothy F Burns & Laura P Stabile
The estrogen signaling pathway is involved in the biology of non-small-cell lung cancer and represents a novel therapeutic target for lung cancer. This is supported by epidemiological evidence, preclinical studies and recent data from clinical trials. Antiestrogens and inhibitors of estrogen synthesis have been shown to inhibit lung tumor growth as well as prevent lung tumorigenesis in preclinical models both in vitro and in vivo.
To view restricted content, please:
